Менеджмент желудочно-кишечных побочных реакций, индуцированных противоопухолевыми средствами


Е.А. Ушкалова

Побочные реакции лекарственных средств занимают важное место в структуре заболеваемости и смертности, сопряжены с огромными экономическими расходами. К препаратам, наиболее часто вызывающим побочные реакции относятся противоопухолевые химиотерапевтические средства. В обзоре рассматриваются методы профилактики и лечения побочных эффектов противоопухолевой терапии в отношении желудочно-кишечного тракта (тошнота, рвота, запоры, диарея), которые встречаются у большинства онкологических больных, особенно в поздних стадиях болезни.

Литература






  1. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. JAMA 1995;274:29-34.
  2. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc 2001;41:192-9.
  3. Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med 1995;155:1949-56.
  4. Leape LL, Brennan TA, Laird N, et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med 1991;324:377-84.
  5. Holland EG, Degruy FV. Drug-Induced Disorders. Am Fam Phys 1997;56:1781-91.
  6. Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997;277:301-6.
  7. Lapeyre-Mestre M, Gary J, Machelard-Roumagnac M, et al. Incidence and cost of adverse drug reactions in a French cancer institute. Eur J Clin Pharmacol 1997;53:19-22.
  8. Baines MJ. Nausea, vomiting, and intestinal obstruction. In: Fallon M, O'Neill B, eds.: ABC of Palliative Care. London:BMJ Books, 1998, pp 16-18.
  9. Wickham R: Nausea and vomiting. In: Yarbo CH, Frogge MH, Goodman M, eds.: Cancer Symptom Management. 2nd ed., Sudbury, Mass: Jones and Bartlett Publishers, 1999, pp 228-263.
  10. Wadler S, Benson AB III, Engelking C, et al. Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 1998;16:3169-78.
  11. Practice Guidelines in Oncology. Rockledge, Pa.: National Comprehensive Cancer Network; 2002.
  12. Morrow GR, Roscoe JA, Kirshner JJ, et al.: Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics. Support Care Cancer 1998;6:244-7.
  13. Lyles JN, Burish TG, Krozely MG, et al. Efficacy of relaxation training and guided imagery in reducing the aversiveness of cancer chemotherapy. J Consult Clin Psychol 1982;50:509-24.
  14. Redd WH, Andresen GV, Minagawa RY. Hypnotic control of anticipatory emesis in patients receiving cancer chemotherapy. J Consult Clin Psychol 1982;50:14-9.
  15. Montgomery GH, Tomoyasu N, Bovbjerg DH, et al. Patients' pretreatment expectations of chemotherapy-related nausea are an independent predictor of anticipatory nausea. Ann Behav Med 1998;20:104-9.
  16. Vasterling J, Jenkins RA, Tope DM, et al. Cognitive distraction and relaxation training for the control of side effects due to cancer chemotherapy. J Behav Med 1993;16:65-80.
  17. Gralla RJ, Osoba D, et al, for the American Society of Clinical Oncology: Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 1999;17:2971-94.
  18. Olver IN, Wolf M, Laidlaw C, et al. A randomised double-blind study of high-dose intravenous prochlorperazine versus high-dose metoclopramide as antiemetics for cancer chemotherapy. Eur J Cancer 1992;28A:1798-1802.
  19. Olver IN, Webster LK, Bishop JF, et al. A dose finding study of prochlorperazine as an antiemetic for cancer chemotherapy. Eur J Cancer Clin Oncol 1989;25:1457-61.
  20. http://www.open.gov.uk/mca/ourwork/monitorsafequalmed/safetymessages/droleptan.htm; http://www.hosmat.com/pharmacovigilance/communique290101.htm
  21. Navari RM. Comparison of intermittent versus continuous infusion metoclopramide in control of acute nausea induced by cisplatin chemotherapy. J Clin Oncol 1989;7:943-6.
  22. Kris MG, Tyson LB, Gralla RJ, et al. Extrapyramidal reactions with high-dose metoclopramide. N Engl J Med 1983;309:433-4.
  23. Kaasa S, Kvaly S, Dicato MA, et al. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group. Eur J Cancer 1990;26:311-4.
  24. De Mulder PH, Seynaeve C, Vermorken JB, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting: a multicenter, randomized, double-blind,crossover study. Ann Int Med 1990;113:834-40.
  25. Beck TM, Hesketh PJ, Madajewicz S, et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1992;10:1969-75.
  26. Finn AL. Toxicity and side effects of ondansetron. Sem Oncol 1992;19(suppl. 10):53-60.
  27. Coates AS, Childs A, Cox K, et al. Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron. Ann Oncol 1992;3:719-22.
  28. Ruff P, Paska W, Goedhals L, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology 1994;51:113-8.
  29. Gebbia V, Cannata G, Testa A, et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting: results of a prospective randomized trial. Cancer 1994;74:1945-52.
  30. Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 2000;18:163-73.
  31. Roscoe JA, Morrow GR, Hickok JT, et al. Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manag 2000;20:113-21.
  32. Morrow GR, Roscoe JA, Kirshner JJ, et al. Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics.Support Care Cancer 1998;6:244-7.
  33. Spitzer TR, Grunberg SM, Dicato MA. Antiemetic strategies for high-dose chemoradiotherapy-induced nausea and vomiting. Support Care Cancer 1998;6:233-6.
  34. Bishop JF, Matthews JP, Wolf MM, et al. A randomised trial of dexamethasone, lorazepam and prochlorperazine for emesis in patients receiving chemotherapy. Eur J Cancer 1992;28:47-50.
  35. Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991;9:675-8.
  36. Zaglama NE, Rosenblum SL, Sartiano GP, et al. Single, high-dose intravenous dexamethasone as an antiemetic in cancer chemotherapy. Oncology 1986;43:27-32.
  37. Klygis LM. Dexamethasone-induced perineal irritation in head injury. Am J Emerg Med 1992;10:268.
  38. Passalacqua R, Cocconi G, Bella M, et al. Double-blind, randomized trial for the control of delayed emesis in patients receiving cisplatin: comparison of placebo vs. adrenocorticotropic hormone (ACTH). Ann Oncol 1992;3:481-5.
  39. Navari RM, Reinhardt RR, et al, for the L-754,030 Antiemetic Trial Group. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. N Engl J Med 1999;340:190-5.
  40. Hesketh PJ, Gralla RJ, Webb RT, et al. Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol 1999;17:338-43.
  41. Pirl WF, Roth AJ. Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psychooncology 2000;9:84-7.
  42. Gralla RJ, Tyson LB, Bordin LA, et al. Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. Cancer Treatment Reports 1984;68:163-72.
  43. Dow GJ, Meyers FH, Stanton W, et al. Serious reactions to oral delta-9-tetrahydrocannabinol in cancer chemotherapy patients. Clin Pharmacol Ther 1984;3:14.
  44. Triozzi PL, Goldstein D, Laszlo J. Contributions of benzodiazepines to cancer therapy. Cancer Invest 1988;6:103-11.
  45. The Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 2000;342:1554-9.
  46. Hagen NA, Foley KM, Cerbone DJ, et al. Chronic nausea and morphine-6-glucuronide. J Pain Symptom Manag 1991;6:125-8.
  47. Derby S, Portenoy RK: Assessment and management of opioid-induced constipation. In: Portenoy RK, Bruera E, eds.:Topics in Palliative Care. Volume 1. New York, NY: Oxford University Press, 1997, pp 95-112.
  48. Bruera E, Seifert L, Watanabe S, et al. Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. J Pain Symptom Manag 1996;11:147-53.
  49. Critchley P, Plach N, Grantham M, et al. Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: a systematic review. J Pain Symptom Manag 2001;22:631-4.
  50. Bruera E, Brenneis C, Michaud M, et al. Continuous Sc infusion of metoclopramide for treatment of narcotic bowel syndrome. Cancer Treatment Reports 1987;71:1121-2.
  51. Pereira J, Bruera E. Successful management of intractable nausea with ondansetron: a case study. J Palliat Care 1996;12:47-50.
  52. Passik SD, Lundberg J, Kirsh KL, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manag 2002;23:526-32.
  53. Derby S, Portenoy RK. Assessment and management of opioid-induced constipation. In: Portenoy RK, Bruera E, eds.:Topics in Palliative Care. Volume 1. New York, NY: Oxford University Press, 1997, pp 95-112.
  54. Fainsinger RL. Integrating medical and surgical treatments in gastrointestinal, genitourinary, and biliary obstruction in patients with cancer. Hematol Oncol Clin N Am 1996;10:173-8.
  55. Mangili G, Franchi M, Mariani A, et al. Octreotide in the management of bowel obstruction in terminal ovarian cancer. Gynecol Oncol 1996;61:345-8.
  56. Barbounis V, Koumakis G, Vassilomanolakis M, et al. Control of irinotecan-induced diarrhea by octreotide after loperamide failure. Support Care Cancer 2001;9:258-60.
  57. Zidan J, Haim N, Beny A, Stein, et al. Octreotide in the treatment of severe chemotherapy-induced diarrhea. Ann Oncol 2001;12:227-9.
  58. Stephen H, Rosenoff MD. CID symptom resolution with long acting octreotide depot. Program and abstracts of the 38th American Society of Clinical Oncology Annual Meeting; May 18-21, 2002;Orlando, Florida. Abstract 1545.



Бионика Медиа